Grant: Collaborative Health Research Projects (NSERC partnered)
McGill University
$200,625.00
Self-illuminating nanoparticles for melanoma therapy
EF 2009-10
Résumé
"Despite vast interest, fluorescent semiconductor quantum dots (QDs) have failed to reach their potential in biomedicine for several reasons. The interface of the particles with biological systems is unstable, poorly characterized, and varies greatly from preparation to preparation. The optical properties of the QDs are also environmentally sensitive, and the particles show widely varying toxicity in different cell lines. Good methods of quantifying their toxicity are difficult to find because of the direct interaction of the particles with reporter dyes. Finally, the cadmium content of most QDs makes them unusable for clinical applications.
However, it is these complex features of QDs that make them interesting and potentially therapeutic. The same properties of small size and reactivity that render these materials cytotoxic also make them excellent as biosensors and anti-cancer agents. QDs have been proposed as agents for photodynamic therapy both alone or linked to a photosensitizer. Our work over the past five years has focused on quantifying the nanoparticle-biomolecule interface and creating visible sensors for processes inside living cells. We now propose to use this knowledge, along with our extensive experience in particle synthesis and our Co-I's expertise in cancer biology, to create nanoparticle-based anti-cancer drugs that are free of heavy metals and which will be able to be translated directly into clinical applications.
Our basic hypothesis is that any molecule that becomes cytotoxic when oxidized or reduced will be more effective when conjugated to a QD, provided that the QD energy levels favour this oxidation or reduction. Malignant cells will demonstrate a different QD labelling pattern than surrounding normal cells.
Our goal is to create heavy-metal-free nanoparticles that target and destroy cancer cells and indicate their action by means of changes in optical properties. These will be readily generalizable to many cancer systems and of direct clinical relevance. The test system we will use in this proposal is a model of melanoma, the deadliest of skin cancers. We will test the anti-cancer activity of our nanoparticles in three types of cultured cells (melanoma cells and their supporting endothelial cells) as well as mice bearing tumours grown of identical cells. This gives a ''molecules to mice'' view of nanotechnology that will be unique in the field."
Programme
Collaborative Health Research Projects (NSERC partnered)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
198818
Name
Nadeau Jay Louise
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Instname2
Unable to allocate
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
Self-illuminating nanoparticles for melanoma therapy
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$200,625
Cihrequipment2
$0
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Nanoparticles
Abstract
"Despite vast interest, fluorescent semiconductor quantum dots (QDs) have failed to reach their potential in biomedicine for several reasons. The interface of the particles with biological systems is unstable, poorly characterized, and varies greatly from preparation to preparation. The optical properties of the QDs are also environmentally sensitive, and the particles show widely varying toxicity in different cell lines. Good methods of quantifying their toxicity are difficult to find because of the direct interaction of the particles with reporter dyes. Finally, the cadmium content of most QDs makes them unusable for clinical applications.
However, it is these complex features of QDs that make them interesting and potentially therapeutic. The same properties of small size and reactivity that render these materials cytotoxic also make them excellent as biosensors and anti-cancer agents. QDs have been proposed as agents for photodynamic therapy both alone or linked to a photosensitizer. Our work over the past five years has focused on quantifying the nanoparticle-biomolecule interface and creating visible sensors for processes inside living cells. We now propose to use this knowledge, along with our extensive experience in particle synthesis and our Co-I's expertise in cancer biology, to create nanoparticle-based anti-cancer drugs that are free of heavy metals and which will be able to be translated directly into clinical applications.
Our basic hypothesis is that any molecule that becomes cytotoxic when oxidized or reduced will be more effective when conjugated to a QD, provided that the QD energy levels favour this oxidation or reduction. Malignant cells will demonstrate a different QD labelling pattern than surrounding normal cells.
Our goal is to create heavy-metal-free nanoparticles that target and destroy cancer cells and indicate their action by means of changes in optical properties. These will be readily generalizable to many cancer systems and of direct clinical relevance. The test system we will use in this proposal is a model of melanoma, the deadliest of skin cancers. We will test the anti-cancer activity of our nanoparticles in three types of cultured cells (melanoma cells and their supporting endothelial cells) as well as mice bearing tumours grown of identical cells. This gives a ''molecules to mice'' view of nanotechnology that will be unique in the field."
Competitiondate
200910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Nadeau, Jay Louise
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $200,625~ $0~